EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL INFARCTION PATIENTS RECEIVING FIBRINOLYTIC THERAPY

S. Indriani, A. Yasa', T. Wasyanto
{"title":"EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL INFARCTION PATIENTS RECEIVING FIBRINOLYTIC THERAPY","authors":"S. Indriani, A. Yasa', T. Wasyanto","doi":"10.30701/ijc.v39i4.798","DOIUrl":null,"url":null,"abstract":"EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL  INFARCTION  PATIENTS RECEIVING FIBRINOLYTIC THERAPY \n  \nSavithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1 \n1Department of Cardiology and Vascular Medicine, Faculty of Medicine, \nUniversitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia \n  \nBackground: Worldwide, coronary heart disease (CHD) is a leading cause of death. Inflammation in CHD and acute myocardial infarction (AMI) is a trigger due to the formation of atheroma plaques in the coronary arteries. N-Acetylcysteine ​​(NAC) can prevent inflammation, remodeling and left ventricular dysfunction, interstitial fibrosis, and improve survival. \nObjective: To determine the effect of NAC on hsCRP levels in patients with acute myocardial infarction who received fibrinolytic therapy. \nMethods: This study was an experimental study with pre and post, single blind and randomization methods on the effect of NAC on hsCRP levels compared to controls carried out in July - August 2018 on the incidence of ST Elevation Myocardial Infarction (STEMI) came to Dr Moewardi Hospital and get fibrinolytic therapy. \nResults: A total of 33 patients were included in this study, there were 15 patients (mean age 58.80 ± 8.54 years) of the control group and 18 patients (mean age 55.45 ± 9.92 years) the treatment group receiving additional therapy of NAC evervescent 600 mg three times a day for three days . This study showed that hsCRP levels after intervention in the control and treatment groups were significantly different with p = 0.001. The level of hsCRP in the control group after administration of NAC had a median of 114.50 mg / L (18.60 - 300.00) while in the treatment group had a median of 18.75 mg / L (5.50 - 102.90). \nConclusion: The addition of NAC 600 mg of therapy three times daily for 3 days can reduce hsCRP levels in patients with STEMI receiving fibrinolytic therapy compared to patients with acute myocardial infarction with ST segment elevation who did not receive additional NAC therapy. \nKeywords: hsCRP, N-Acetylcysteine, acute myocardial infarction \n. \n  \nPENGARUH N-ACETYLCYSTEIN TERHADAP HSCRP PADA PASIEN INFARK MIOKARD AKUT DENGAN ELEVASI SEGMEN ST YANG MENDAPAT TERAPI FIBRINOLITIK \n  \nSavithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1 \nDepartemen Ilmu Penyakit Jantung dan Pembuluh Darah, Fakultas Kedokteran \nUniversitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia \n  \nLatar Belakang: Di seluruh dunia, penyakit jantung koroner (PJK) merupakan penyebab utama kematian. Inflamasi pada PJK dan infark miokard akut (IMA) merupakan pemicu akibat terbentuknya plak ateroma pada arteri koroner. N-Acetylcysteine (NAC) dapat mencegah inflamasi, remodeling dan disfungsi ventrikel kiri, fibrosis interstisial, dan meningkatkan survival. \nTujuan: Untuk mengetahui pengaruh  NAC terhadap kadar hsCRP pada pasien infark miokard akut yang mendapatkan terapi fibrinolitik. \nMetode:  Penelitian ini merupakan penelitian eksperimental dengan metode pre dan post, single blind dan randomisasi  mengenai pengaruh NAC terhadap kadar hsCRP dibandingkan dengan kontrol yang dilakukan pada bulan Juli - Agustus 2018 terhadap paien Infark Miokard Akut dengan Elevasi Segmen ST (IMA-EST) yang datang ke  Rumah Sakit Dr Moewardi dan mendapat terapi fibrinolitik. \nHasil: Sebanyak 33 pasien diikutsertakan pada penelitian ini, terdapat 15 pasien (rerata usia 58.80±8.54 tahun) kelompok kontrol dan 18 pasien (rerata usia 55.45±9.92 tahun) kelompok perlakuan yang mendapat terapi tambahan NAC evervescent 600 mg tiga kali sehari selama tiga hari.  Penelitian ini menunjukkan bahwa kadar hsCRP sesudah dilakukan intervensi pada kelompok kontrol dan perlakuan berbeda bermakna dengan nilai p = 0.001. Kadar hsCRP pada kelompok kontrol  sesudah pemberian NAC memiliki median 114.50 mg/L(18.60 – 300.00) sedangkan pada kelompok perlakuan memiliki median 18.75 mg/L(5.50 – 102.90). \nKesimpulan: Pemberian terapi tambahan NAC 600 mg tiga kali sehari selama 3 hari dapat menurunkan kadar hsCRP pada pasien infark miokard akut dengan elevasi segmen ST yang mendapat terapi fibrinolitik dibanding pasien infark miokard akut dengan elevasi segmen ST yang tidak mendapat terapi tambahan NAC. \nKata Kunci: hsCRP,  N-Acetylcysteine, infark miokard akut","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Majalah Kardiologi Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30701/ijc.v39i4.798","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL  INFARCTION  PATIENTS RECEIVING FIBRINOLYTIC THERAPY   Savithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1 1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia   Background: Worldwide, coronary heart disease (CHD) is a leading cause of death. Inflammation in CHD and acute myocardial infarction (AMI) is a trigger due to the formation of atheroma plaques in the coronary arteries. N-Acetylcysteine ​​(NAC) can prevent inflammation, remodeling and left ventricular dysfunction, interstitial fibrosis, and improve survival. Objective: To determine the effect of NAC on hsCRP levels in patients with acute myocardial infarction who received fibrinolytic therapy. Methods: This study was an experimental study with pre and post, single blind and randomization methods on the effect of NAC on hsCRP levels compared to controls carried out in July - August 2018 on the incidence of ST Elevation Myocardial Infarction (STEMI) came to Dr Moewardi Hospital and get fibrinolytic therapy. Results: A total of 33 patients were included in this study, there were 15 patients (mean age 58.80 ± 8.54 years) of the control group and 18 patients (mean age 55.45 ± 9.92 years) the treatment group receiving additional therapy of NAC evervescent 600 mg three times a day for three days . This study showed that hsCRP levels after intervention in the control and treatment groups were significantly different with p = 0.001. The level of hsCRP in the control group after administration of NAC had a median of 114.50 mg / L (18.60 - 300.00) while in the treatment group had a median of 18.75 mg / L (5.50 - 102.90). Conclusion: The addition of NAC 600 mg of therapy three times daily for 3 days can reduce hsCRP levels in patients with STEMI receiving fibrinolytic therapy compared to patients with acute myocardial infarction with ST segment elevation who did not receive additional NAC therapy. Keywords: hsCRP, N-Acetylcysteine, acute myocardial infarction .   PENGARUH N-ACETYLCYSTEIN TERHADAP HSCRP PADA PASIEN INFARK MIOKARD AKUT DENGAN ELEVASI SEGMEN ST YANG MENDAPAT TERAPI FIBRINOLITIK   Savithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1 Departemen Ilmu Penyakit Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia   Latar Belakang: Di seluruh dunia, penyakit jantung koroner (PJK) merupakan penyebab utama kematian. Inflamasi pada PJK dan infark miokard akut (IMA) merupakan pemicu akibat terbentuknya plak ateroma pada arteri koroner. N-Acetylcysteine (NAC) dapat mencegah inflamasi, remodeling dan disfungsi ventrikel kiri, fibrosis interstisial, dan meningkatkan survival. Tujuan: Untuk mengetahui pengaruh  NAC terhadap kadar hsCRP pada pasien infark miokard akut yang mendapatkan terapi fibrinolitik. Metode:  Penelitian ini merupakan penelitian eksperimental dengan metode pre dan post, single blind dan randomisasi  mengenai pengaruh NAC terhadap kadar hsCRP dibandingkan dengan kontrol yang dilakukan pada bulan Juli - Agustus 2018 terhadap paien Infark Miokard Akut dengan Elevasi Segmen ST (IMA-EST) yang datang ke  Rumah Sakit Dr Moewardi dan mendapat terapi fibrinolitik. Hasil: Sebanyak 33 pasien diikutsertakan pada penelitian ini, terdapat 15 pasien (rerata usia 58.80±8.54 tahun) kelompok kontrol dan 18 pasien (rerata usia 55.45±9.92 tahun) kelompok perlakuan yang mendapat terapi tambahan NAC evervescent 600 mg tiga kali sehari selama tiga hari.  Penelitian ini menunjukkan bahwa kadar hsCRP sesudah dilakukan intervensi pada kelompok kontrol dan perlakuan berbeda bermakna dengan nilai p = 0.001. Kadar hsCRP pada kelompok kontrol  sesudah pemberian NAC memiliki median 114.50 mg/L(18.60 – 300.00) sedangkan pada kelompok perlakuan memiliki median 18.75 mg/L(5.50 – 102.90). Kesimpulan: Pemberian terapi tambahan NAC 600 mg tiga kali sehari selama 3 hari dapat menurunkan kadar hsCRP pada pasien infark miokard akut dengan elevasi segmen ST yang mendapat terapi fibrinolitik dibanding pasien infark miokard akut dengan elevasi segmen ST yang tidak mendapat terapi tambahan NAC. Kata Kunci: hsCRP,  N-Acetylcysteine, infark miokard akut
n -乙酰半胱氨酸对接受纤溶治疗的急性心肌梗死患者HSCRP水平的影响
N-乙酰半胱氨酸对N-乙酰半胱氨酸在急性心肌梗死中对HSCRP水平的影响接受纤溶性治疗的梗塞患者WIBRININOLYTIC治疗的患者Savithri Indriani1,Ahmad Yasa1,Trisulo Wasyanto1 Sebelas Maret大学医学院心血管和血管医学系,RS Dr Moewardi,Surakarta,印度尼西亚背景:在世界范围内,冠心病是死亡的主要原因。冠心病和急性心肌梗死(AMI)的炎症是冠状动脉中动脉粥样硬化斑块形成的诱因。N-乙酰半胱氨酸(NAC)可以预防炎症、重塑和左心室功能障碍、间质纤维化,并提高生存率。目的:探讨NAC对接受纤溶治疗的急性心肌梗死患者hsCRP水平的影响。方法:本研究是一项实验性研究,采用前后、单盲和随机方法,与对照组相比,研究NAC对hsCRP水平的影响。该研究于2018年7月至8月对ST段抬高型心肌梗死(STEMI)的发病率进行了研究。结果:本研究共纳入33例患者,其中对照组15例(平均年龄58.80±8.54岁),治疗组18例(平均岁55.45±9.92岁)接受NAC泡腾剂600mg的额外治疗,每天3次,为期3天。本研究表明,干预后对照组和治疗组的hsCRP水平存在显著差异,p=0.001。NAC给药后,对照组的hsCRP水平的中位数为114.50 mg/L(18.60-300.00),而治疗组的中位数为18.75 mg/L(5.50-102.90)。没有接受额外NAC治疗的ST段抬高的梗死患者。关键词:hsCRP,N-乙酰半胱氨酸,急性心肌梗死。SHCRP中的前一个N-乙酰半胱氨酸整个世界,冠心病是死亡的主要原因。PJK和急性心肌梗死(IMA)的炎症是冠状动脉中动脉粥样硬化斑块形成的诱因。N-乙酰半胱氨酸(NAC)可以预防炎症、重塑和左心室功能障碍、间质纤维化,并提高生存率。目的:探讨NAC对接受纤溶治疗的急性心肌梗死患者hsCRP的影响。方法:结果:本研究共招募了33名患者,对照组有15名患者(平均年龄58.80±8.54岁),治疗组有18名患者(均值55.45±9.92岁)接受了额外的NAC泡腾剂600mg,每日三次,为期三天。本研究表明,干预后对照组和治疗组的hsCRP发生率有显著差异,p=0.001。NAC给药后,对照组的hsCRP率中位数为114.50 mg/L(18.60-300.00),而治疗组的hsCR率中位数为18.75 mg/L(5.50-102.90)。未接受额外NAC治疗的ST段抬高的急性心肌梗死。关键词:hsCRP,[UNK]N-乙酰半胱氨酸,急性心肌梗死
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
6
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信